Phase II study of neoadjuvant therapy with epirubicin and docetaxel for women with locally advanced breast cancer.

被引：0
|
作者：
Holter, JL
Tfayli, A
Venkattapa, S
Bova, A
Howard, O
机构：
[1] Univ Oklahoma, Moore, OK USA
[2] Univ Oklahoma, Oklahoma City, OK USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：98S / 98S
页数：1
相关论文
共 50 条
  • [1] Epirubicin and docetaxel as neoadjuvant treatment of locally advanced breast cancer: a phase II study
    Lombardi, D.
    Scalone, S.
    Crivellari, D.
    La Mura, N.
    Miolo, G.
    Murrone, A.
    Perin, T.
    Coran, F.
    Candiani, E.
    Massarut, S.
    Veronesi, A.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S229 - S229
  • [2] Epirubicin and docetaxel as neoadjuvant treatment of locally advanced breast cancer: a phase II study
    Lombardi, Davide
    Scalone, Simona
    Crivellari, Diana
    Magri, Maria Donatella
    La Mura, Nicoletta
    Miolo, GianMaria
    Murrone, Antonio
    Perin, Tiziana
    Coran, Francesco
    Candiani, Ezio
    Massarut, Samuele
    Veronesi, Andrea
    TUMORI JOURNAL, 2010, 96 (02): : 229 - 233
  • [3] A phase I/II study of imatinib and docetaxel as neoadjuvant therapy in locally advanced breast cancer
    Haley, B. B.
    Ashfaq, R.
    DeHaas, M.
    Ramaswami, A.
    Sikder, K.
    Tripathy, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [4] A Phase II Study of Concurrent Docetaxel, Epirubicin and Cyclophosphamide as a Neoadjuvant Chemotherapy Regimen in Patients with Locally Advanced Breast Cancer
    Yao, Xin
    Hosenpud, Janet
    Chitambar, Christopher R.
    Charlson, John
    Cheng, Yee Chung
    JOURNAL OF CANCER, 2012, 3 : 145 - 151
  • [5] Phase II trial of neoadjuvant docetaxel with or without bevacizumab in patients with locally advanced breast cancer.
    Overmoyer, B
    Silverman, P
    Leeming, R
    Shenk, R
    Lyons, J
    Ziats, N
    Jesberger, J
    Dumadag, L
    Remick, S
    Chen, H
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 58S - 58S
  • [6] Phase II trial of neoadjuvant docetaxel with or without bevacizumab in patients with locally advanced breast cancer.
    Overmoyer, B
    Silverman, P
    Leeming, R
    Shenk, R
    Lyons, J
    Jesberger, J
    Hartman, P
    Dumadag, L
    Chen, H
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S106 - S106
  • [7] Neoadjuvant gemcitabine, epirubicin, and docetaxel (GET). Preliminary results from a multicenter phase II trial in inflammatory and locally advanced breast cancer.
    Yardley, DA
    Whitworth, P
    Greco, FA
    Burris, HA
    White, M
    Thomas, M
    Dunbar, L
    Yost, K
    Hainsworth, JD
    BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 : S54 - S54
  • [8] A phase II trial of docetaxel, capecitabine, and cisplatin as neoadjuvant chemotherapy for locally advanced breast cancer.
    Lu, YS
    Kuo, SH
    Su, WP
    Yang, CH
    Hsu, C
    Yang, TL
    Huang, CS
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 93S - 93S
  • [9] A phase II trial of docetaxel (taxotere) in combination with epirubicin as neoadjuvant chemotherapy in patients with locally advanced breast cancer
    Fried, G
    Zidan, J
    Epelbaum, R
    Keren-Rosenberg, S
    Basher, W
    Steckelman, I
    Kogan, F
    Haim, N
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S69 - S70
  • [10] A Phase II Trial of Neoadjuvant Gemcitabine, Epirubicin, and Docetaxel as Primary Treatment of Patients With Locally Advanced or Inflammatory Breast Cancer
    Yardley, Denise A.
    Peacock, Nancy W.
    Dickson, Natalie R.
    White, Melissa B.
    Vazquez, Elizabeth R.
    Foust, John T.
    Grapski, Richard
    Hendricks, Linda K.
    Scott, William L.
    Hainsworth, John D.
    CLINICAL BREAST CANCER, 2010, 10 (03) : 217 - 223
12345